Abstract: The inventors report two siblings presenting recurrent EBV infection and Hodgkin lymphoma caused by a homozygous loss-of-function mutation in RASGRP1, a T-cell specific nucleotide exchange factor (GEF) known to activate the RAS-induced MAPK/ERK kinases pathway. In response to TCR stimulation, RASGRP1-deficient T cells exhibited defective ERK kinases activation and impaired proliferation that was restored by expression of wild-type RASGRP1. Thus, these results identify a novel primary immunodeficiency that highlights T-cell proliferation and offers the opportunity to develop RASGRP1 inhibitor for inhibiting T cell proliferation in a subject in need thereof.

Abstract: A reusable battery indicator includes a voltage sensor, a communication circuit communicatively connected to the voltage sensor, an antenna operatively coupled to the communication circuit, and a connection mechanism having a connector and a retainer. The connector and the retainer are electrically connected to the voltage sensor, and the connector is adapted to be removably connected to a first battery terminal, thereby providing an electrical connection between the voltage sensor and the first battery terminal. The retainer is adapted to removably secure the voltage sensor to a can of a battery, thereby providing an electrical connection between the voltage sensor and the can of the battery. An electrical circuit is completed between the voltage sensor and the first battery terminal and between the voltage sensor and the can. The connection mechanism includes part of an electrical lock and key assembly.

Abstract: The present invention relates to methods and pharmaceutical compositions for inhibiting lymphocyte proliferation in a subject in need thereof. In particular, the invention relates to a CTP synthase 1 (CTPS1) inhibitor for use in a method for inhibiting lymphocyte proliferation in a subject in need thereof. The invention also relates to a method for screening a plurality of test substances useful for inhibiting lymphocyte proliferation in a subject in need thereof comprising the steps consisting of i) testing each of the test substances for its ability to inhibit CTPS1 activity or expression and ii) identifying the test substance which inhibits CTPS1 activity or expression thereby to identify a test substance useful for inhibiting lymphocyte proliferation in a subject in need thereof.

Abstract: The present invention relates to methods and pharmaceutical compositions for inhibiting lymphocyte proliferationin a subject in need thereof. In particular, the invention relates to a CTP synthase 1 (CTPS1) inhibitor for use in a method for inhibiting lymphocyte proliferationin a subject in need thereof. The invention also relates to a method for screening a plurality of test substances useful for inhibiting lymphocyte proliferationin a subject in need thereof comprising the steps consisting of i) testing each of the test substances for its ability to inhibit CTPS1 activity or expression and ii) identifying the test substance which inhibits CTPS1 activity or expression thereby to identify a test substance useful for inhibiting lymphocyte proliferationin a subject in need thereof.

Abstract: The invention relates to a new gene and protein involved in V(D)J recombination and repair. The invention also relates to methods of diagnosis and therapy using these genes and protein. The invention also relates to transgenic animals over- and under-expressing said gene.

Abstract: The invention related to a new gene and protein involved in V(D)J recombination and/or DNA repair. The invention also relates to methods of diagnosis and therapy using these gene and protein. The invention also relates to transgenic animals over- or under-expressing said gene.

Abstract: The invention related to a new gene and protein involved in V(D)J recombination and/or DNA repair. The invention also relates to methods of diagnosis and therapy using these gene and protein. The invention also relates to transgenic animals over- or under-expressing said gene.

Abstract: The invention relates to a method for preventing and treating graft failure in humans comprising injecting a specific anti-LFA-1 monoclonal antibody.